Novartis to buy breast cancer drug candidate from Synnovation in up to $3 billion deal

Summary

Novartis has agreed to acquire a breast cancer drug candidate from Synnovation Therapeutics in a deal valued at up to $3 billion, strengthening its oncology pipeline. The agreement includes an upfront payment and milestone-based payouts tied to development and regulatory progress.

The experimental therapy targets a common genetic mutation linked to hormone receptor-positive breast cancer, an area of ongoing unmet medical need.

BASEL/FRANKFURT, March 20, 2026 — Novartis said on Friday it has agreed to acquire a breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, as the Swiss drugmaker expands its oncology portfolio.

Under the agreement, Novartis will make an upfront payment of about $2 billion, with additional milestone payments linked to the drug’s development, regulatory approvals and commercial performance, the company said.

The acquisition centres on an experimental oral therapy currently in early-stage clinical trials that targets mutations in the PI3K pathway, which are commonly associated with hormone receptor-positive, HER2-negative breast cancer.

Novartis said the treatment could potentially address limitations seen with existing therapies in the same class, particularly around tolerability and long-term use, though it remains under investigation.

The company plans to study the candidate both as a standalone treatment and in combination with other established therapies used in breast cancer care.

Breast cancer remains one of the most common cancers globally, and patients with specific genetic mutations continue to face limited treatment options, particularly in advanced stages of the disease.

The transaction is expected to close in the first half of 2026, subject to customary regulatory approvals.

Why this matters

• Oncology focus: Strengthens Novartis’ position in targeted cancer therapies.
• Pipeline expansion: Adds an early-stage asset with potential in a large patient population.
• Industry trend: Reflects continued dealmaking in biotech to secure next-generation treatments.

FAQs

Q1. What is Novartis acquiring?

A breast cancer drug candidate from Synnovation Therapeutics that is currently in early clinical development.

Q2. What type of cancer does it target?

Hormone receptor-positive, HER2-negative breast cancer linked to PI3K pathway mutations.

Q3. When will the deal close?

It is expected to close in the first half of 2026, pending regulatory approvals.